LBA1 Ceralasertib (C) + durvalumab (D) in patients (pts) with locally advanced (LA) or metastatic (m) NSCLC who progressed on or after anti-PD-(L)1 and platinum-based chemotherapy (CT): Results from LATIFY

4.5 (0.4-31.9) 3.8 (0-31.7)3.0 (0.3-27.6)CI, confidence interval; HR, hazard ratio; mo, months.Conclusions: C+D did not demonstrate a statistically significant improvement in OS vs docetaxel.C+D had manageable toxicity and AEs were consistent with the known safety profiles of each agent.